[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604302":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":15,"locations":21,"responsibleParty":55,"collaborators":7,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":7,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":7,"enrollmentInfo":65,"targetDuration":7,"studyType":68,"phases":7,"briefSummary":69,"conditions":70,"keywords":7,"overallStatus":72,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"International Extranodal Lymphoma Study Group (IELSG)","OTHER",null,[9,13],{"name":10,"affiliation":11,"role":12},"Marco Paulli, MD","Unit of Pathology, IRCCS Policlinico San Matteo Foundation and Department of Molecular Medicine, University of Pavia (IT)","STUDY_CHAIR",{"name":14,"affiliation":11,"role":12},"Marco Lucioni, MD",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"International Extranodal Lymphoma Study Group - IELSG","CONTACT","+41 58 666 7321","ielsg@ior.usi.ch",[22,39],{"facility":23,"status":7,"city":24,"state":7,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Fondazione IRCCS Policlinico San Matteo Pavia","Pavia","27100","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],9.15917,45.19205,{"lat":32,"lon":31},[35,37],{"name":14,"role":18,"phone":7,"phoneExt":7,"email":36},"marco.lucioni@unipv.it",{"name":14,"role":38,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":40,"status":7,"city":41,"state":7,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Oncology Institute of Southern Switzerland and Institute of Oncology Research","Bellinzona","6500","Switzerland","CH",{"type":29,"coordinates":46},[47,48],9.01703,46.19278,{"lat":48,"lon":47},[51,54],{"name":52,"role":18,"phone":7,"phoneExt":7,"email":53},"Maria Cristina Pirosa, MD","maria.pirosa@eoc.ch",{"name":52,"role":38,"phone":7,"phoneExt":7,"email":7},{"type":56,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100604302","characterization-of-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-pcns-dlbcl-by-multiomic-approach-100604302",false,"NCT07147751","Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach","Inclusion Criteria:\n\n1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.\n2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.\n3. Availability of the baseline and follow-up annotations\n\nExclusion Criteria:\n\n1. Established immunodeficiency conditions.\n2. Secondary CNS localizations of DLBCL\n3. Transformed DLBCL","ALL","18 Years",{"count":66,"type":67},100,"ESTIMATED","OBSERVATIONAL","PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.\n\nUnderstanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.",[71],"Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)","NOT_YET_RECRUITING","2026-06-18",{"date":75,"type":76},"2026-06-22","ACTUAL",{"date":78,"type":67},"2026-09",{"date":80,"type":67},"2029-12",{"name":5,"class":6},2]